Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 12:10:43-8.
doi: 10.4137/CMO.S32821. eCollection 2016.

Resectable Cholangiocarcinoma: Reviewing the Role of Adjuvant Strategies

E Una Cidon  1
Affiliations
Review

Resectable Cholangiocarcinoma: Reviewing the Role of Adjuvant Strategies

E Una Cidon. Clin Med Insights Oncol. .

Abstract

Cholangiocarcinoma is a very heterogeneous and rare group of neoplasms originating from the perihilar, intra-, or extrahepatic bile duct epithelium. It represents only 3% of gastrointestinal cancers, although their incidence is increasing as its mortality increases. Surgical resection is the only potentially curative option, but unfortunately the resectability rate is low. Overall, these malignancies have got a very poor prognosis with a five-year survival rate of 5-10%. Although the five-year survival rate increases to 25-30% in the cases amenable to surgery, only 10-40% of patients present with resectable disease. Therefore, it is necessary to optimize the benefit of adjuvant strategies after surgery to increase the rate of curability. This study reviewed the role of adjuvant chemotherapy in resectable bile duct cancers.

Keywords: adjuvant chemotherapy; bile duct carcinomas; cholangiocarcinoma.

PubMed Disclaimer

References

    1. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341:1368–78. - PubMed
    1. Nagorney DM, Donohue JH, Farnell MB, Schleck CD, Ilstrup DM. Outcomes after curative resections of cholangiocarcinoma. Arch Surg. 1993;128:871–7. discussion 877–9. - PubMed
    1. Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg. 2013;258:129–40. - PubMed
    1. Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y. Surgical resection of hilar cholangio-carcinoma: analysis of survival and postoperative complications. World J Surg. 2007;31:1256–63. - PubMed
    1. Edge SB. American Joint Committee on Cancer Staging Manual. 7th ed. New York: Sprimger; 2010. p. 219. - PubMed